TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2020

Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial.

Jinmei Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.